Wedbush Analysts Initiate Coverage on EXACT Sciences Co. (EXAS)
Tuesday, June 28, 2021 9:40 AM



Equities research analysts at Wedbush initiated coverage on shares of EXACT Sciences Co. (NASDAQ: EXAS) in a research note to investors on Tuesday. The analysts set an "outperform" rating and a $10.00 price target on the stock.

Separately, analysts at Auriga initiated coverage on shares of EXACT Sciences Co. in a research note to investors on Tuesday, May 3rd. They set a "buy" rating and a $10.00 price target on the stock. Also, analysts at Benchmark Co. initiated coverage on shares of EXACT Sciences Co. in a research note to investors on Thursday, April 28th. They set a "buy" rating and a $9.00 price target on the stock.

Shares of EXACT Sciences Co. opened at 8.18 on Wednesday. EXACT Sciences Co. has a 52 week low of $3.15 and a 52 week high of $9.24. The stock's 50-day moving average is $7.39 and its 200-day moving average is $6.55. The company has a market cap of $427.2 million.

EXACT Sciences Co. last announced its quarterly results on Tuesday, May 3rd. The company reported ($0.08) earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.09) EPS by $0.01. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was down 20.20% on a year-over-year basis. On average, analysts predict that EXACT Sciences Co. will post $-0.14 EPS next quarter.

Exact Sciences Corporation (Exact) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. It has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. The Company’s focus is on the commercial development and seeking United States Food and Drug Administration (FDA) clearance and approval of its stool-based deoxyribonucleic acid (DNA) (sDNA), colorectal cancer screening product. Its sDNA screening test, is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Pre-cancerous polyps are present in approximately 5% of the population over 50 years of age in the United States. Its sDNA screening test can detect pre-cancers and cancers early. By detecting pre-cancers and cancers early with the sDNA-based test, affected patients can be referred to colonoscopy, during which the polyp or lesion can be removed.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.


 

Sponsors

Advertisement


Advertisement